Here are the 10-K annual reports from Longevity Health Holdings (XAGE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow XAGE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XAGE filings page.
Longevity Health Holdings, Inc. is a microcap aesthetics company focused on regenerative bio-aesthetic skincare and haircare under the Elevai and Carmell brands, using exosome- and platelet-rich plasma-based formulations sold through physicians, medical spas, distributors, and online channels. The company has paused development of its bone and tissue healing candidates to focus on cosmetics.
In March 2026, it completed a private placement of 689,656 common shares at $0.29 for approximately $200,000 with International Capital Partners LLC and simultaneously transitioned leadership, with former Chairman and CEO Rajiv Shukla departing and Janakiram Ajjarapu becoming Chairman and CEO. Shukla receives $30,000 per month for 12 months, with potential extensions and a contingent $480,000 bonus payment tied to a larger capital raise.
As of June 30, 2025, non-affiliate common stock held a market value of about $3.3 million, and 2,475,321 shares were outstanding as of March 27, 2026. The filing highlights substantial competition in the cosmetics industry, reliance on third-party manufacturing and human-tissue-derived inputs, and significant regulatory exposure, including new obligations under the Modernization of Cosmetic Regulation Act of 2022. Management discloses that substantial additional capital will be needed and acknowledges a conclusion that there is substantial doubt about the company’s ability to continue as a going concern.